Pharsight

Xyosted (autoinjector) patents expiration

XYOSTED (AUTOINJECTOR)'s oppositions filed in EPO
Can you believe XYOSTED (AUTOINJECTOR) received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE44847 ANTARES PHARMA INC Needle assisted jet injector
Aug, 2019

(4 years ago)

USRE44846 ANTARES PHARMA INC Needle assisted jet injector
Aug, 2019

(4 years ago)

US8562564 ANTARES PHARMA INC Prefilled syringe jet injector
Jan, 2026

(1 year, 7 months from now)

US9629959 ANTARES PHARMA INC Prefilled syringe jet injector
Jan, 2026

(1 year, 7 months from now)

US9180259 ANTARES PHARMA INC Prefilled syringe jet injector
Jan, 2026

(1 year, 7 months from now)

US9533102 ANTARES PHARMA INC Prefilled syringe jet injector
Jan, 2026

(1 year, 7 months from now)

US10478560 ANTARES PHARMA INC Prefilled syringe injector
Jan, 2026

(1 year, 7 months from now)

US11446441 ANTARES PHARMA INC Prefilled syringe injector
Jan, 2026

(1 year, 7 months from now)

US8021335 ANTARES PHARMA INC Prefilled syringe jet injector
Oct, 2026

(2 years from now)

US11497753 ANTARES PHARMA INC Hazardous agent injection system
Mar, 2030

(5 years from now)

US10279131 ANTARES PHARMA INC Injection device with cammed RAM assembly
Jul, 2031

(7 years from now)

US10357609 ANTARES PHARMA INC Needle assisted jet injection device having reduced trigger force
Aug, 2031

(7 years from now)

US11446440 ANTARES PHARMA INC Needle assisted injection device having reduced trigger force
Aug, 2031

(7 years from now)

US10905827 ANTARES PHARMA INC Injection device with cammed ram assembly
Aug, 2031

(7 years from now)

US11844804 ANTARES PHARMA INC Administration of testosterone compositions
Jun, 2033

(8 years from now)

US10821072 ANTARES PHARMA INC Needle assisted jet injection administration of testosterone compositions
Jun, 2033

(8 years from now)

US10881798 ANTARES PHARMA INC Needle assisted injection device having reduced trigger force
Feb, 2034

(9 years from now)

US11771646 ANTARES PHARMA INC Needle assisted jet injection administration of testosterone compositions
Apr, 2034

(9 years from now)

US11160751 ANTARES PHARMA INC Hematocrit modulation through needle assisted jet injection of testosterone
Oct, 2034

(10 years from now)

US10912782 ANTARES PHARMA INC Needle assisted injection administration of testosterone compositions
Feb, 2035

(10 years from now)

US10238662 ANTARES PHARMA INC Needle assisted jet injection administration of testosterone compositions
Feb, 2035

(10 years from now)

US11813435 ANTARES PHARMA INC Needle assisted injection device having reduced trigger force
Feb, 2035

(10 years from now)

US11191908 ANTARES PHARMA INC Syringe shock absorber for use in an injection device
Oct, 2035

(11 years from now)

US9744302 ANTARES PHARMA INC Needle assisted jet injection device having reduced trigger force
Nov, 2035

(11 years from now)

US9950125 ANTARES PHARMA INC Needle assisted jet injection administration of testosterone compositions
Sep, 2036

(12 years from now)

US10646495 ANTARES PHARMA INC Testosterone ester triglyceride formulations
Aug, 2038

(14 years from now)

Xyosted (Autoinjector) is owned by Antares Pharma Inc.

Xyosted (Autoinjector) contains Testosterone Enanthate.

Xyosted (Autoinjector) has a total of 26 drug patents out of which 2 drug patents have expired.

Expired drug patents of Xyosted (Autoinjector) are:

  • USRE44847
  • USRE44846

Xyosted (Autoinjector) was authorised for market use on 28 September, 2018.

Xyosted (Autoinjector) is available in solution;subcutaneous dosage forms.

Xyosted (Autoinjector) can be used as method of administering testosterone enanthate subcutaneously, method of operating an injection device.

The generics of Xyosted (Autoinjector) are possible to be released after 30 August, 2038.

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 28, 2021

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using TESTOSTERONE ENANTHATE ingredient

Market Authorisation Date: 28 September, 2018

Treatment: Method of operating an injection device; Method of administering testosterone enanthate subcutaneously

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

XYOSTED (AUTOINJECTOR) family patents

Family Patents